AU2012332111B2 - Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia - Google Patents

Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia Download PDF

Info

Publication number
AU2012332111B2
AU2012332111B2 AU2012332111A AU2012332111A AU2012332111B2 AU 2012332111 B2 AU2012332111 B2 AU 2012332111B2 AU 2012332111 A AU2012332111 A AU 2012332111A AU 2012332111 A AU2012332111 A AU 2012332111A AU 2012332111 B2 AU2012332111 B2 AU 2012332111B2
Authority
AU
Australia
Prior art keywords
compound
cells
catenin
beta
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012332111A
Other languages
English (en)
Other versions
AU2012332111A1 (en
Inventor
Kapil N. Bhalla
Stephen Horrigan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Cat Pharmaceuticals LLC
Original Assignee
Beta Cat Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Cat Pharmaceuticals LLC filed Critical Beta Cat Pharmaceuticals LLC
Publication of AU2012332111A1 publication Critical patent/AU2012332111A1/en
Application granted granted Critical
Publication of AU2012332111B2 publication Critical patent/AU2012332111B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012332111A 2011-11-06 2012-11-06 Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia Active AU2012332111B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556245P 2011-11-06 2011-11-06
US61/556,245 2011-11-06
PCT/US2012/063746 WO2013067547A1 (en) 2011-11-06 2012-11-06 METHODS FOR TREATMENT OF DISEASES AND DISORDERS RELATED TO TRANSDUCIN β-LIKE PROTEIN 1 (TBL 1) ACTIVITY, INCLUDING MYELOPROLIFERATIVE NEOPLASIA AND CHRONIC MYELOID LEUKEMIA

Publications (2)

Publication Number Publication Date
AU2012332111A1 AU2012332111A1 (en) 2014-05-22
AU2012332111B2 true AU2012332111B2 (en) 2016-11-17

Family

ID=48192926

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012332111A Active AU2012332111B2 (en) 2011-11-06 2012-11-06 Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia

Country Status (15)

Country Link
US (1) US9238030B2 (https=)
EP (1) EP2773607B1 (https=)
JP (1) JP6063472B2 (https=)
KR (1) KR102336767B1 (https=)
CN (1) CN103917514B (https=)
AU (1) AU2012332111B2 (https=)
BR (1) BR112014010584A2 (https=)
CA (1) CA2853491C (https=)
EA (1) EA027770B1 (https=)
ES (1) ES2624427T3 (https=)
IL (1) IL232452A (https=)
MX (1) MX354653B (https=)
SG (1) SG11201402056XA (https=)
WO (1) WO2013067547A1 (https=)
ZA (1) ZA201403003B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963475B2 (en) * 2015-07-28 2018-05-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
TW201718495A (zh) * 2015-07-28 2017-06-01 貝塔貓製藥股份有限公司 蒽-9, 10-二酮二肟化合物前驅藥及其用途
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
WO2019099836A1 (en) * 2017-11-16 2019-05-23 Northwestern University Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases
WO2019229001A1 (en) * 2018-05-30 2019-12-05 Otto-Von-Guericke-Universität Magdeburg Compounds for the treatment of jak2-v617f-associated cmn
CN119215047A (zh) * 2024-10-11 2024-12-31 浙江大学 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147713A1 (en) * 2007-05-24 2008-12-04 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
WO2010059142A1 (en) * 2008-11-21 2010-05-27 Avalon Pharmaceuticals Anthraquinone dioximes and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2152258T (pt) * 2007-05-10 2016-08-18 Avalon Pharmaceuticals Derivados de fluoreno, antraceno, xanteno, dibenzosuberona e acridina e suas utilizações
JP2013501792A (ja) * 2009-08-10 2013-01-17 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔ／ｂ−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用
US20120157500A1 (en) * 2009-08-24 2012-06-21 Weikang Tao Jak inhibition blocks rna interference associated toxicities
JP2013505968A (ja) 2009-10-01 2013-02-21 シーエスエル、リミテッド フィラデルフィア染色体陽性白血病の治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147713A1 (en) * 2007-05-24 2008-12-04 The Regents Of The University Of California Wnt signaling inhibitors, and methods for making and using them
WO2010059142A1 (en) * 2008-11-21 2010-05-27 Avalon Pharmaceuticals Anthraquinone dioximes and uses thereof

Also Published As

Publication number Publication date
ZA201403003B (en) 2017-08-30
KR20140089418A (ko) 2014-07-14
NZ624446A (en) 2016-01-29
JP2014534229A (ja) 2014-12-18
EA201490937A1 (ru) 2014-08-29
EA027770B1 (ru) 2017-08-31
CA2853491C (en) 2019-12-10
KR102336767B9 (ko) 2025-01-08
BR112014010584A2 (pt) 2017-05-02
JP6063472B2 (ja) 2017-01-18
US20130143920A1 (en) 2013-06-06
CN103917514A (zh) 2014-07-09
MX354653B (es) 2018-03-07
KR102336767B1 (ko) 2021-12-10
IL232452A (en) 2017-01-31
IL232452A0 (en) 2014-06-30
ES2624427T3 (es) 2017-07-14
CN103917514B (zh) 2016-11-16
EP2773607A1 (en) 2014-09-10
WO2013067547A1 (en) 2013-05-10
EP2773607B1 (en) 2017-03-29
AU2012332111A1 (en) 2014-05-22
SG11201402056XA (en) 2014-10-30
HK1198440A1 (en) 2015-04-24
CA2853491A1 (en) 2013-05-10
US9238030B2 (en) 2016-01-19
EP2773607A4 (en) 2015-03-11
MX2014005498A (es) 2016-05-05

Similar Documents

Publication Publication Date Title
AU2012332111B2 (en) Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
US10583129B2 (en) Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
JP7045985B2 (ja) Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法
HK1251162A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
US11413284B2 (en) Protein kinase C inhibitors for treatment of uveal melanoma
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
CN112912075B (zh) 治疗前列腺癌的组合疗法
US20190365680A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
HK1198440B (en) Treatment of diseases and disorders related to transducin beta-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
EP3638690A1 (en) Methods to treat gliomas using a stat3 inhibitor
NZ624446B2 (en) Methods for treatment of diseases and disorders related to transducin ?-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
US9907797B2 (en) Combination therapies for overcoming resistance to mitotic agents during chemotherapy
JP2020083849A (ja) ガンを治療又は予防するための医薬組成物
WO2023224961A1 (en) Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
HK1253277B (zh) Ep4受体拮抗剂用於治疗nash相关肝癌的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)